Drug Profile
Research programme: antiviral therapeutics - National Institutes of Health/Amarna Therapeutics
Latest Information Update: 28 Jun 2018
Price :
$50
*
At a glance
- Originator Amarna Therapeutics; National Institutes of Health (USA)
- Class RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B; Hepatitis C; HIV-1 infections
Most Recent Events
- 28 Jun 2018 No recent reports of development identified for research development in Hepatitis-B in Netherlands (Parenteral)
- 28 Jun 2018 No recent reports of development identified for research development in Hepatitis-C in Netherlands (Parenteral)
- 28 Jun 2018 No recent reports of development identified for research development in HIV-1-infections in Netherlands (Parenteral)